Why the study?
Viral respiratory infections can exacerbate chronic cardiovascular disease and trigger new adverse cardiovascular complications, warranting a review of their cardiovascular impact and COVID-19-related circulatory pathology.
Key points are not available for this paper at this time.
Population
Patients with viral respiratory infections and COVID-19
Design
Narrative review
Answers are grounded in this paper and cite their sources.
Supports heightened cardiovascular monitoring during viral infections; leaves open optimal prevention strategies pending prospective trials.
Viral respiratory infections (VRI) are the most prevalent type of infectious diseases and constitute one of the most common causes of contact with medical care. Regarding the pathophysiology of the cardiovascular system, VRI can not only exacerbate already existing chronic cardiovascular disease (such as coronary artery disease or heart failure) but also trigger new adverse events or complications (e.g., venous thromboembolism), the latter particularly in subjects with multimorbidity or disease-related immobilization. In the current paper, we provide a narrative review of diverse cardiovascular complications of VRI as well as summarize available data on the pathology of the circulatory system in the course of coronavirus disease 2019 (COVID-19).
No takes yet. Share an insight, caveat, or question.
Franczuk et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: